DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer

Simon Gampenrieder; G. Rinnerthaler; Walter Pulverer; Andreas Weinhäusel; Clemens Hufnagl; H Hackl; Cornelia Hauser-Kornberger; R. Greil

DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer

Simon Gampenrieder (Speaker), G. Rinnerthaler, Walter Pulverer, Andreas Weinhäusel, Clemens Hufnagl, H Hackl, Cornelia Hauser-Kornberger, R. Greil

Molecular Diagnostics

Research output: Poster presentation without proceedings › peer-review

Original language	English
Publication status	Published - 2016
Event	39th San Antonio Breast Cancer Symposium 2016 - Duration: 6 Dec 2016 → 10 Dec 2016

Conference

Conference	39th San Antonio Breast Cancer Symposium 2016
Period	6/12/16 → 10/12/16

Research Field

Former Research Field - Health and Bioresources

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@conference{dfbf7cf0f4fe47c0b565da2b33dae6e9,

title = "DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer",

author = "Simon Gampenrieder and G. Rinnerthaler and Walter Pulverer and Andreas Weinh{\"a}usel and Clemens Hufnagl and H Hackl and Cornelia Hauser-Kornberger and R. Greil",

year = "2016",

language = "English",

note = "39th San Antonio Breast Cancer Symposium 2016 ; Conference date: 06-12-2016 Through 10-12-2016",

}

TY - CONF

T1 - DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer

AU - Rinnerthaler, G.

AU - Pulverer, Walter

AU - Weinhäusel, Andreas

AU - Hufnagl, Clemens

AU - Hackl, H

AU - Hauser-Kornberger, Cornelia

AU - Greil, R.

A2 - Gampenrieder, Simon

PY - 2016

Y1 - 2016

M3 - Poster presentation without proceedings

T2 - 39th San Antonio Breast Cancer Symposium 2016

Y2 - 6 December 2016 through 10 December 2016

ER -